The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 21, 2018
Filed:
Jun. 22, 2016
Applicant:
Immport Therapeutics, Inc., Irvine, CA (US);
Inventors:
Philip Felgner, Rancho Santa Fe, CA (US);
Xiaowu Liang, La Jolla, CA (US);
Maria Laura Gennaro, New York, NY (US);
Assignee:
Immport Therapeutics, Inc., Irvine, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/15 (2006.01); C12N 15/10 (2006.01); A61K 39/015 (2006.01); A61K 39/02 (2006.01); A61K 39/04 (2006.01); A61K 39/118 (2006.01); A61K 39/245 (2006.01); A61K 39/285 (2006.01); A61K 39/385 (2006.01); C07K 14/005 (2006.01); G01N 33/566 (2006.01); A61K 39/12 (2006.01); G01N 33/569 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1068 (2013.01); A61K 39/015 (2013.01); A61K 39/0208 (2013.01); A61K 39/0225 (2013.01); A61K 39/04 (2013.01); A61K 39/098 (2013.01); A61K 39/118 (2013.01); A61K 39/12 (2013.01); A61K 39/245 (2013.01); A61K 39/285 (2013.01); A61K 39/385 (2013.01); C07K 14/005 (2013.01); G01N 33/566 (2013.01); G01N 33/5695 (2013.01); G01N 33/56911 (2013.01); G01N 33/56916 (2013.01); G01N 33/56927 (2013.01); G01N 33/56983 (2013.01); G01N 33/56994 (2013.01); G01N 33/6854 (2013.01); A61K 2039/60 (2013.01); C12N 2710/16621 (2013.01); C12N 2710/16622 (2013.01); C12N 2710/16634 (2013.01); C12N 2710/24122 (2013.01); C12N 2710/24134 (2013.01); G01N 2333/35 (2013.01); G01N 2469/20 (2013.01); Y02A 50/401 (2018.01); Y02A 50/412 (2018.01);
Abstract
Contemplated compositions, devices, and methods are drawn to various antigens from the pathogenand their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.